scholarly journals Gambaran Usia dan Stadium Klinis Pasien Kanker Payudara yang dilakukan Pemeriksaan Imunohistokimia di Rumah Sakit Abdul Wahab Sjahranie pada Tahun 2018

2020 ◽  
Vol 8 (2) ◽  
pp. 126-140
Author(s):  
Ade Yusuf Yulianto ◽  
Hadi Irawiraman ◽  
P.M.T. Mangalindung Ompusunggu
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Hormone Receptors ◽  
Clinical Stage ◽  
Descriptive Study ◽  
Regional Hospital ◽  
Breast Cancer Patients ◽  
Immunohistochemical Examination ◽  
Ki 67 ◽  
Her 2

ABSTRACKBreast cancer still occupies the highest incidence of all types of malignancies in women. Based on data recorded at Abdul Wahab Sjahrenie Hospital, 200 new cases are found each year. Immunohistochemical profile examination has been used extensively as a basis for classifying breast cancer molecularly. Expression of hormone receptors (ER, PR) and HER-2 found in immunohistochemical examinations are useful for determining therapeutic options that fit the patient's needs. The purpose of this descriptive study was to determine the characteristics of the immunohistochemical profile of breast cancer patients in Abdul Wahab Sjahranie Regional Hospital Samarinda in the January-December 2018 period based on age and clinical stage that had been examined by immunohistochemical examination including the expression of ER PR, Ki-67 and HER2. Method: This study used a cross-sectional descriptive study design by taking secondary data from breast cancer patients who had performed immunohistochemical examinations at Abdul Wahab Sjahranie Regional Hospital Samarinda in the January 2018 - December 2018 period. From 479 breast cancer patients came to Abdul Wahab Regional Hospital Sjahranie Samarinda, only 177 (37.18%) patients did immunohistochemical examinations. Most patients aged 40-49 were 65 patients (36.7%) had breast cancer, the highest clinical stage IIIB with 92 cases (52%), the Ki-67 with severe highest interpretation, range> 30% with 73 patients (41.2%), more positive ER than negative, in 93 patients (52.5%), while negative examination results 84 patients (47.5%). PR is the same as ER, which is 96 patients (54.2%), while negative examination results are 81 patients (45.8%). Most HER-2 results were negative, in 109 patients (61.6%). In this study the highest number of cases of breast cancer patients ranged between the ages of 40-49 years and at least aged 70 years and above. The clinical stage is most often found in stage IIIB (advanced). Ki-67 examination was found most frequently in severe interpretations. Examination of estrogen receptors is found to be most widely in positive interpretation. Positive progesterone tests to be most widely than negative examinations. Her-2 examination was found to be most widely in negative interpretation Keywords: Immunohistochemical examination, Hormone receptors, HER-2, Clinical Stadium

The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients

Tumor Biology ◽  
2015 ◽  
Vol 37 (6) ◽  
pp. 7675-7684 ◽  
Author(s):  
Yan-Yun Zhu ◽  
Wen Si ◽  
Tie-Feng Ji ◽  
Xiao-Qin Guo ◽  
Yi Hu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Clinical Significance ◽  
Hormone Receptors ◽  
Breast Cancer Patients ◽  
Metastatic Lesions ◽  
Her 2

scholarly journals Ki-67 Labeling Index in Primary Invasive Breast Cancer from Sudanese Patients: A Pilot Study

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
Khalid Dafaallah Awadelkarim ◽  
Renato Mariani-Costantini ◽  
Ihsan Osman ◽  
Massimo Costanzo Barberis
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Tumor Size ◽  
Interquartile Range ◽  
Labeling Index ◽  
Breast Cancer Patients ◽  
Ki 67 ◽  
Significant Group ◽  
Cancer Subtypes ◽  
Her 2

Ki-67 labeling index has been linked to patient outcome in breast cancer patients. However, very few published reports have examined Ki-67 labeling index in African breast cancer patients. Sixty-two Sudanese breast cancer patients with primary invasive tumors were immunostained for Ki-67, ER, PR, Her-2/neu, CK5/6, and CK17. Ki-67 labeling index ranged from 0% to 50%, with a median of 5% (interquartile range 0–10). Low Ki-67 labeling index (immunostaining < 10%) was detected in 43/62 (69.4%) with a median of 0 (interquartile range 0–5), whereas high Ki-67 labeling index (immunostaining ≥ 10%) was revealed in 19/62 (30.6%) with a median of 20 (interquartile range 12–26). Ki-67 labeling index was significantly associated with tumor grade (P=0.022, Mann-Whitney U Test). There were no significant group differences between Ki-67 labeling index and ER (P=0.43), PR (P=0.7), Her-2/neu (P=0.45), CK5/6 (P=0.29), CK17 (P=0.55), pathologic stage (P=0.4), tumor histology (P=0.99), breast cancer subtypes (P=0.47), tumor size (P=0.16), and age at diagnosis (P=0.6). These results suggested that Ki-67 labeling index correlates with tumor differentiation and not with the tumor size or any other tested marker in Sudanese breast cancers. Thus, Ki-67 labeling index could be considered as a reliable measure of tumor proliferative fraction in Sudan.

scholarly journals Investigation of the change in the biological structure of the tumor in metastatic breast cancer

2021 ◽  
Vol 8 (3) ◽  
pp. 171-174
Author(s):  
Veysel Haksoyler ◽  
Tolga Koseci ◽  
Timucin Cil ◽  
Berna Bozkurt Duman ◽  
Polat Olgun ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Cancer Patients ◽  
Hormone Receptors ◽  
Tumor Biology ◽  
Metastatic Breast ◽  
Breast Cancer Patients ◽  
Metastatic Site ◽  
Significant Difference ◽  
Her 2

Objective: When metastasis develops in some breast cancer patients, hormone receptors (HR) and Human Epidermal Growth Factor-2 (Her-2) status can change and the tumor alters its character. We tried to determine the rate of these changes in tumor biology in 110 patients that we followed in our clinic and performed the change of the biopsy from the metastatic site (re-bx). We aimed to determine the biological changes of tumors and, contribute to the literature by examining the relationship of these changes with the adjuvant endocrine treatments (ET) or chemotherapy type (CT). Material and Methods: We included 110 metastatic breast cancer patients in our study. These patients had previously completed their local treatments followed by CT, and those with positive HR completed ET. After the first metastasis developed in the patients, we performed metastasectomy or biopsy from the metastatic site. Results: The median ki-67 value was 25% at the time of primary diagnosis and 30% in re-bx. 20.9% of patients estrogen receptor (ER), 31.8%  of patients progesterone receptor (PR) and 26.3% of patients Her-2 changed when metastasis developed. Conclusions: We found that the metastatic tumor has more aggressive properties than the primary tumor. Adjuvant chemotherapy and endocrine treatments or the location of metastasis did not make a significant difference in tumor biology.

The role of Ki-67 in molecular breast cancer classification.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 583-583
Author(s):  
George Stathopoulos ◽  
Nikolaos Malamos ◽  
Christos Markopoulos ◽  
Athanasios Polychronis ◽  
Sotirios Rigatos ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Triple Negative ◽  
Progesterone Receptors ◽  
Molecular Classification ◽  
Breast Cancer Patients ◽  
Luminal A ◽  
Ki 67 ◽  
Luminal B ◽  
Her 2

583 Background: The Ki-67 antigen was identified the involvement in early steps of polymerase I-dependent ribosomal RNA synthesis. Although it seems that the protein has an important function in cell division, its exact role is still obscure and there is little published work on its overall function. The aim of the present study is to evaluate the contribution of Ki-67 level in respect of tumor recurrence in molecular classified groups of breast cancer patients. Methods: Breast cancer tumor samples were examined for histological confirmation and for estrogen and progesterone receptors, c-erb-B2 expression, proliferation with Grade and Ki-67. Ki-67 was divided in percentage levels, up to 20 and higher than 20%. Immunohistochemistry and Fluorescence in situ hybridization is described for the results of ER, PR, c-erb-B2, Ki-67 biomarkers. Formaldehyde – fixed breast samples were paraffin wax embedded and processed for paraffin sections. The primary antibodies used were: The monoclinal antibody ID5 (M7047, Dakocytomation, Carpinteria, CA) for the detection of ER, the monoclonal anti-PR antibody 636 was used. For the detection of Ki-67 we used monoclonal mouse anti-human Ki-67 MIB-1. The patients molecular classification was Luminal A, Luminal B, Her-2 subtype and basal cell (triple negative). Results: 847 breast cancer patients were recruited. 291 were group as Luminal A, 228 as Luminal B, 221 Her-2 subtype and 107 triple negative. Follow-up was from 3 years to 15 years since diagnosis. It was found that in Luminal A patients, none had Ki-67 higher than 20% and the recurrence was in 10.65%. In Luminal B, the Ki-67 was higher than 20% in 61% of the patients and recurrence 23.68%. In Her-2 subtype >20% Ki-67 was 78.94%, recurrence 17.19%. In triple negative > 20% Ki-67 was in 68.75% and recurrence in 29.90% of the patients. Conclusions: The data presented here indicate that Ki-67 level may be considered as one of valuable biomarkers in breast cancer patients process and recurrence.

scholarly journals Expressions of IGF-1R and Ki-67 in breast cancer patients with diabetes mellitus and an analysis of biological characteristics

2021 ◽  
Vol 38 (1) ◽  
Author(s):  
Xiaolu Yan ◽  
Zhe Gao ◽  
Ye Zhou ◽  
Fei Gao ◽  
Qingxia Li
Keyword(s):  
Breast Cancer ◽  
Diabetes Mellitus ◽  
Cancer Patients ◽  
Histological Grade ◽  
Clinical Stage ◽  
Biological Characteristics ◽  
Control Group ◽  
Breast Cancer Patients ◽  
Ki 67 ◽  
Patients With Diabetes

Objectives: There is a cross-link of insulin and insulin-like growth factor-1 (IGF-1) with each other’s receptors. The present study was carried out to explore the relationship of Type-2 diabetes mellitus (T2DM) with the occurrence and development of breast cancer by analyzing the expression of IGF-1R and Ki-67, as well as the biological characteristics in breast cancer patients with and without diabetes mellitus. Methods: A total of 102 cases of breast cancer patients with T2DM admitted in Hebei General Hospital from January 2019 to December 2020 were selected and grouped in T2DM group. While the control group included 106 cases of breast cancer patients without diabetes mellitus in the same period. Further comparison was conducted focusing on the general data, clinical stage, tumor histological grade, molecular classification and prognosis, and the expressions of IGF-1R and Ki-67 in breast cancer tissue between groups. Results: Compared with control group, patients in T2DM group were elderly and accounted for a larger proportion of post-menopause (p<0.05), yet with no significant difference in body mass and family history (p>0.05). Compared with control group, T2DM group had advanced clinical stage, higher histological grade, and more common molecular type, with statistical differences between groups (p<0.05). Furthermore, there were higher proportions of local recurrence, lymph node metastasis and distant metastasis in T2DM group than those in control group, yet with no statistical significance (p>0.05). While statistical difference was found in the comparison of the 5-year survival rate, which was lower in T2DM group than that in control group (p<0.05). In addition, compared with control group, there were significant increase in both the expressions of IGF-1R and Ki-67 in T2DM group (p<0.05). Conclusions: T2DM may be one of the risk factors affecting the occurrence, development and prognosis of breast cancer, which may decrease the 5-year survival of breast cancer patients. Besides, high expressions of IGF-1R and Ki-67 may be the key factors for poor prognosis of breast cancer patients with diabetes mellitus. doi: https://doi.org/10.12669/pjms.38.1.4718 How to cite this:Yan X, Gao Z, Zhou Y, Gao F, Li Q. Expressions of IGF-1R and Ki-67 in breast cancer patients with diabetes mellitus and an analysis of biological characteristics. Pak J Med Sci. 2022;38(1):---------. doi: https://doi.org/10.12669/pjms.38.1.4718 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Sign in / Sign up

Export Citation Format

Share Document